Los Angeles Capital Management LLC Invests $3.26 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Los Angeles Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 17,028 shares of the biopharmaceutical company’s stock, valued at approximately $3,259,000.

Several other institutional investors and hedge funds have also modified their holdings of ALNY. First Trust Direct Indexing L.P. raised its holdings in Alnylam Pharmaceuticals by 13.3% during the fourth quarter. First Trust Direct Indexing L.P. now owns 2,898 shares of the biopharmaceutical company’s stock valued at $555,000 after buying an additional 340 shares in the last quarter. Mach 1 Financial Group LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $841,000. Gilbert & Cook Inc. boosted its position in Alnylam Pharmaceuticals by 7.7% during the fourth quarter. Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company’s stock worth $850,000 after purchasing an additional 317 shares during the period. Truist Financial Corp bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $474,000. Finally, Semanteon Capital Management LP acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $308,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 13th. HC Wainwright reissued a “buy” rating and issued a $395.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 5th. Royal Bank of Canada reissued an “outperform” rating and set a $235.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Finally, Citigroup decreased their price objective on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a report on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $215.88.

Alnylam Pharmaceuticals Stock Up 1.3 %

ALNY stock opened at $152.33 on Monday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $218.88. The company has a market cap of $19.19 billion, a P/E ratio of -56.84 and a beta of 0.41. The business has a fifty day moving average of $149.65 and a 200-day moving average of $165.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same quarter in the previous year, the business earned ($1.40) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.43 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.